Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
69 hedge funds and large institutions have $374M invested in Aimmune Therapeutics in 2016 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 28 increasing their positions, 10 reducing their positions, and 6 closing their positions.
183% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 6
180% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 10
19% more funds holding
Funds holding: 58 → 69 (+11)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
21% less capital invested
Capital invested by funds: $476M → $374M (-$102M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$14.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.32M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$8.13M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$7.84M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$2.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.4M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$642K |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$594K |
| 4 |
FAM
Fred Alger Management
New York
|
-$318K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$268K |
AIMT Hedge Fund Activity: Q1 2016 in Review
69 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q1 2016, worth a combined $374M — down 21% from $476M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new AIMT positions and 6 closed out — a net gain of 11 holders — while 28 added to existing stakes and 10 trimmed.
The largest buyer was Eagle Asset Management, adding an estimated $14.1M. The largest seller was Fidelity Investments, cutting an estimated $18.4M.
- 69 institutional investors held Aimmune Therapeutics (AIMT) as of Q1 2016, up from 58 in Q4 2015.
- Funds reported $374M of Aimmune Therapeutics stock for Q1 2016, down 21% quarter-over-quarter.
- 17 funds opened new Aimmune Therapeutics positions in Q1 2016 and 6 closed out, a net change of +11 holders.
- The largest Aimmune Therapeutics buyer in Q1 2016 was Eagle Asset Management, an estimated $14.1M added.
- The largest Aimmune Therapeutics seller in Q1 2016 was Fidelity Investments, an estimated $18.4M sold.
Based on aggregated 13F filings for Q1 2016.